ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Cancer Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1635630
This article is part of the Research TopicAdvances in Targeted Therapy and Biomarker Research for Endocrine-Related Cancers, Volume IIView all 8 articles
Clinical Characteristics and Survival Outcomes of Extrapulmonary Neuroendocrine Carcinomas: A Retrospective Study
Provisionally accepted
- Harbin Medical University Cancer Hospital, Harbin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Extrapulmonary neuroendocrine carcinomas (EPNECs) are rare, heterogeneous, and aggressive malignancies with limited evidence to guide management. This study aimed to investigate the clinical characteristics, prognostic factors, and treatment outcomes of EPNEC patients. Methods: We retrospectively analyzed 343 EPNEC patients treated at Harbin Medical University Cancer Hospital from May 2011 to December 2023. Data on demographics, primary tumor sites, tumor markers (CEA and NSE), treatments, and survival were collected. Kaplan–Meier and Cox proportional hazards models were used to evaluate prognostic factors, and subgroup analyses were performed for treatment modalities. Results: The median overall survival (OS) for the cohort was 23.7 months. Prognosis varied significantly by primary site, with genitourinary tumors showing the most favorable outcomes and hepatopancreatobiliary tumors the poorest. Independent predictors of worse survival included advanced stage (HR = 1.94, p < 0.001), lymph node metastasis (HR = 1.48, p = 0.02), elevated CEA (HR = 1.49, p = 0.04), and elevated NSE (HR = 1.48, p = 0.03). Patients with both CEA and NSE levels elevated had the shortest OS (p < 0.0001). Treatment effects were stage-specific: surgery improved survival only in stage I/II patients (HR = 0.26, p = 0.01), whereas chemotherapy (HR = 0.67, p = 0.02) and radiotherapy (HR = 0.45, p < 0.001) provided significant benefits in stage III/IV patients. Radiotherapy showed consistent benefit across most subgroups, including those with elevated biomarkers. Conclusion: EPNEC prognosis is influenced by tumor site, stage, lymph node involvement, and biomarker levels. Surgery is optimal for early-stage disease (I/II), while chemotherapy and radiotherapy provide survival benefits in advanced-stage (III/IV) patients. Combined CEA and NSE elevation indicates a particularly poor prognosis. These findings highlight the importance of individualized, stage-and biomarker-driven therapeutic strategies for EPNECs.
Keywords: Extrapulmonary neuroendocrine carcinoma, survival analysis, CEA, NSE, prognostic factors
Received: 26 May 2025; Accepted: 13 Oct 2025.
Copyright: © 2025 Xu, Li, Xu, Lian and LU. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Haibo LU, luhaibo@hrbmu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.